报价延迟最少15分钟:2026/03/29 21:08 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.97 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.22/-0.62
|
|
企业价值
1.55B
|
| 资产负债 |
|
每股账面净值
2.99
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
655.35M
|
|
每股收益
4.50
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets. |
